Cyclopharm (ASX:CYC) secures an agreement with University Hospitals (UH) in Cleveland, Ohio, for the immediate installation of its Technegas® system across 11 clinical locations, expanding the Company`s presence in the US healthcare market.

🏥 11-site rollout: UH will install Technegas® across all 11 clinical locations over the coming weeks, with site preparation already completed to enable immediate deployment.
🇺🇸 US expansion: The agreement strengthens Cyclopharm`s footprint in northern Ohio and adds another leading US academic health system to its growing network of reference sites.
📈 Recurring revenue: Each installation is expected to generate ongoing revenue through per-patient ventilation imaging procedures, as well as consumables and service income as procedure volumes increase.

"What makes this agreement particularly significant is its immediacy. Rather than a staged rollout over time, UH has elected to install Technegas® system-wide, at 11 locations, over the next few weeks. This deepens our recurring revenue base and reflects the confidence UH has placed in Technegas® at enterprise scale.” – Cyclopharm Managing Director and CEO James McBrayer

What happens when Australia`s biggest mining company starts running low on its most profitable metal? BHP`s latest operational review has just shown that while copper output hit the top of its target range, BHP expects copper production to fall about 12% in the year ahead, mainly due to declining ore grades at its mine in Chile.

Copper is now more important than ever because it is used in EVs, data centres and the energy transition. As a result it also accounts for around half of BHP`s profits, highlighting the reliance on a metal that`s becoming increasingly difficult to mine.

#mining #copper #stocks #money #finance

Oceana Metals (ASX:OCN) is preparing to begin a major 20,000m drilling program at its Serra Negra Rare Earths Project in Brazil, alongside an extensive re-assaying program of historic drill core. The work is designed to determine the size, continuity and potential scale of the rare earths mineralisation ahead of an initial resource estimate planned for 2026. Ahead of presenting at Noosa Mining, Oceana Metals Chair Russell Curtin joins The Stock Network`s Lel Smits to discuss why Serra Negra could emerge as a significant new rare earths discovery.

🇧🇷 Drilling campaign and exploration upside in Brazil
🪓 Resource growth and upcoming catalysts

Neurotech International (ASX:NTI) receives US FDA clearance for its Investigational New Drug (IND) application for NTI164, opening the pathway for US clinical development and supporting the Company`s global registration strategy.

🇺🇸 FDA milestone: The US FDA clears Neurotech International’s IND application for its NTI164, allowing the Company to commence its proposed US clinical development program for this oral cannabinoid drug therapy.
🧪 Global strategy: The planned US study is designed to complement the Australian Phase 3 "Beyond Harmony" trial, supporting future global regulatory submissions.
🌍 Commercial pathway: The milestone strengthens Neurotech International’s global commercialisation strategy and supports ongoing discussions with potential strategic partners.

"Together with our ongoing Australian Phase 3 trial, the data generated under the FDA-cleared IND is expected to create an integrated clinical and regulatory evidence package for NTI164, supporting the Company`s global development, registration and commercialisation strategy." – Neurotech International CEO and Managing Director Anthony Filippis

US Inflation just came in lower than expected, and markets celebrated. So why did the head of the Fed refuse to join the party?

US inflation cooled to 3.5% in June, down from 4.2%. That’s great news for investors, on the surface, but almost all of that drop came from falling petrol prices, after the Iran ceasefire calmed oil markets in June.

Here`s the catch, that ceasefire has already collapsed, and oil has spiked back up so the very thing that cooled inflation has now reversed, and this data doesn`t capture it yet.

That`s why the Fed chair, Kevin Warsh, wasn`t celebrating. He warned against treating this as `mission accomplished`. The lesson is that inflation data is a rear-view mirror. It tells you where prices were, not where they`re going.

#fintok #money #US #Wallstreet #money

Epiminder (ASX:EPI) is a medical device company developing the FDA-approved Minder® System, a breakthrough subscalp EEG monitoring technology designed to improve the diagnosis and management of epilepsy. The Company has now achieved its 50th patient enrolment in the landmark DETECT clinical trial ahead of schedule, with 20 leading US epilepsy centres, including Mayo Clinic, Harvard, Stanford, Yale, Duke and the University of Pennsylvania, actively recruiting patients as the study builds momentum toward its target of 210 participants. Epiminder CEO Rohan Hoare joins The Stock Network`s Lel Smits to discuss why accelerating enrolment in DETECT validates the Minder System and what this means for the Company`s commercial opportunity.

🔬 Clinical momentum and the unmet need
⚕️ The path to commercial adoption
🇺🇲Why leading US hospitals are backing DETECT

Far East Gold (ASX:FEG) has reaffirmed its recommendation that shareholders reject Xingye Gold`s takeover offer following the release of its Supplementary Target`s Statement and a second review by independent expert Lonergan Edwards. Far East Gold Managing Director & CEO Shane Menere joins Lel Smits from The Stock Network to discuss the latest developments in the takeover process, respond to Xingye`s criticisms, and outline why the Board believes shareholders should retain exposure to the company`s growth strategy.

⚒️ Independent expert reaffirms the Board`s position
🪓 Responding to Xingye`s criticisms
🔍 Looking beyond the takeover
🛘 Fair value for shareholders
🌏 Xingye`s broader corporate strategy
⛏️ Final message to shareholders

What`s the smartest way to make money in a gold rush?

Back in 1849 most people who dug for gold went broke but the ones who got rich sold the picks, shovels and jeans to the miners. They won no matter who struck gold.

Investors call this a “picks and shovels” play. Don`t bet on who wins the race. Sell the tools to everyone who needs them. It`s happening again now with AI. Over the last week SK Hynix Inc (NASDAQ:SKHY) listed on the Nasdaq, raising $26.5 billion.

SK Hynix doesn`t build the flashy AI models, it makes the memory chips every AI system needs, including Nvidia`s. SK Hynix is selling shovels in the AI gold rush.

So next time everyone`s chasing the shiny winner, ask who is selling the tools they all depend on? Because in a gold rush, the shovel seller never has a bad day.

#finance #investing #IPO #stocks #AI